Gene Information
Gene symbol: CDKN2A
Gene name: cyclin-dependent kinase inhibitor 2A
HGNC ID: 1787
Synonyms: CDK4I, p16, INK4a, MTS1, CMM2, ARF, p19, p14, INK4, p16INK4a, p19Arf
Related Genes
| # | Gene Symbol | Number of hits |
| 1 | APC | 1 hits |
| 2 | BRCA1 | 1 hits |
| 3 | BRCA2 | 1 hits |
| 4 | HBB | 1 hits |
| 5 | HRAS | 1 hits |
| 6 | KRAS | 1 hits |
| 7 | TP53 | 1 hits |
| 8 | TWSG1 | 1 hits |
Related Sentences
| # | PMID | Sentence |
| 1 | 7585472 | At the 9p arm is located the p16 (MTS1) TSG and probably others with an effect on various human tumours such as acute lymphoblastic leukaemia, bladder cancer, gliomas, malignant mesotheliomas, melanomas and non-small cell lung carcinomas. |
| 2 | 7585472 | In addition, the 17q arm harbours BRCA1 TSG which is responsible for approximately 80% of the familial breast/ovarian cancer cases. |
| 3 | 7585472 | In addition, BRCA1 TSG is implicated in the development of laryngeal tumours. |
| 4 | 8950667 | A family history of pancreatic adenocarcinoma is not common in patients with this disease, but recent research has shown that pancreatic adenocarcinoma can be a feature of cancer susceptibility syndromes associated with germline mutations in p16, BRCA1, BRCA2, and APC. |
| 5 | 8950667 | A family history of pancreatic adenocarcinoma is not common in patients with this disease, but recent research has shown that pancreatic adenocarcinoma can be a feature of cancer susceptibility syndromes associated with germline mutations in p16, BRCA1, BRCA2, and APC. |
| 6 | 8950667 | Somatic mutations in p16, BRCA2, and APC have also been reported in pancreatic cancer; however, K-RAS mutations appear to be the commonest oncogenic alteration. |
| 7 | 8950667 | Somatic mutations in p16, BRCA2, and APC have also been reported in pancreatic cancer; however, K-RAS mutations appear to be the commonest oncogenic alteration. |
| 8 | 9796697 | p53 mutation with frequent novel condons but not a mutator phenotype in BRCA1- and BRCA2-associated breast tumours. |
| 9 | 9796697 | The status of p53 was investigated in breast tumours arising in germ-line carriers of mutant alleles of BRCA1 and BRCA2 and in a control series of sporadic breast tumours. p53 expression was detected in 20/26 (77%) BRCA1-, 10/22 (45%) BRCA2-associated and 25/72 (35%) grade-matched sporadic tumours. |
| 10 | 9796697 | Analysis of additional genes, p16INK4, Ki-ras and beta-globin revealed absence or very low incidence of mutations, suggesting that the higher frequency of p53 mutation in the BRCA-associated tumours does not reflect a generalized increase in susceptibility to the acquisition of somatic mutation. |
| 11 | 9796697 | Furthermore, absence of frameshift mutations in the polypurine tracts present in the coding sequence of the TGF beta type II receptor (TGF beta IIR) and Bax implies that loss of function of BRCA1 or BRCA2 does not confer a mutator phenotype such as that found in tumours with microsatellite instability (MSI). p21Waf1 was expressed in BRCA-associated tumours regardless of p53 status and, furthermore, some tumours expressing wild-type p53 did not express detectable p21Waf1. |